Cargando…

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deeb, Dorrah, Gao, Xiaohua, Arbab, Ali S., Barton, Kenneth, Dulchavsky, Scott A., Gautam, Subhash C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143824/ https://www.ncbi.nlm.nih.gov/pubmed/21799944 http://dx.doi.org/10.3390/cancers2041779

Ejemplares similares

Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
por: Gao, Xiaohua, et al.
Publicado: (2011)

Inhibition of Telomerase Activity by Oleanane Triterpenoid CDDO-Me in Pancreatic Cancer Cells is ROS-Dependent
por: Deeb, Dorrah, et al.
Publicado: (2013)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
por: GAO, XIAOHUA, et al.
Publicado: (2015)

Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways
por: Deeb, Dorrah, et al.
Publicado: (2014)

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity
por: Casares, Laura, et al.
Publicado: (2022)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
por: Kulkarni, Ajit A., et al.
Publicado: (2013)

Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2
por: DEEB, DORRAH, et al.
Publicado: (2014)

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells
por: DEEB, DORRAH, et al.
Publicado: (2015)

The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage
por: Amirova, Kristiana M., et al.
Publicado: (2023)

The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection
por: Tran, Thi A, et al.
Publicado: (2008)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
por: Cleasby, Anne, et al.
Publicado: (2014)

MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP)
por: Arbab, Ali S, et al.
Publicado: (2011)

Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008)

A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE
por: Wei, Hsi-Ju, et al.
Publicado: (2017)

A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer
por: So, Jae Young, et al.
Publicado: (2014)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease()
por: Aminzadeh, Mohammad A., et al.
Publicado: (2013)

CDDO-Me reveals USP7 as a novel target in ovarian cancer cells
por: Qin, Dongjun, et al.
Publicado: (2016)

CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages
por: Ball, Michael S., et al.
Publicado: (2016)

Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
por: Yang, Lichuan, et al.
Publicado: (2009)

The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia reperfusion injury in mice
por: Liu, Manchang, et al.
Publicado: (2013)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
por: Aminzadeh, Mohammad A., et al.
Publicado: (2014)

Triterpenoid CDDO-Me induces ROS generation and up-regulates cellular levels of antioxidative enzymes without induction of DSBs in human peripheral blood mononuclear cells
por: Beinke, Christina, et al.
Publicado: (2020)

Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells
por: Qin, Dong-Jun, et al.
Publicado: (2015)

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer
por: Ball, Michael S., et al.
Publicado: (2020)

T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages
por: Torres, Gretel M., et al.
Publicado: (2022)

The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes
por: Elliott, Sarah, et al.
Publicado: (2003)

The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner
por: Moerland, Jessica A., et al.
Publicado: (2023)

Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2
por: Xing, Yifan, et al.
Publicado: (2012)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
por: El-Ashmawy, Mariam, et al.
Publicado: (2014)

The triterpenoid CDDO-imidazolide ameliorates mouse liver ischemia-reperfusion injury through activating the Nrf2/HO-1 pathway enhanced autophagy
por: Xu, Dongwei, et al.
Publicado: (2017)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

CDDO-Me Abrogates Aberrant Mitochondrial Elongation in Clasmatodendritic Degeneration by Regulating NF-κB-PDI-Mediated S-Nitrosylation of DRP1
por: Lee, Duk-Shin, et al.
Publicado: (2023)

Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme
por: Tsai, Tai-Hsin, et al.
Publicado: (2021)

Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR
por: Yore, Mark M., et al.
Publicado: (2011)

CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1
por: Kim, Ji-Eun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bgtjj38k23c30ktahpqtjlg73c